ATE330599T1 - Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt - Google Patents

Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt

Info

Publication number
ATE330599T1
ATE330599T1 AT00902628T AT00902628T ATE330599T1 AT E330599 T1 ATE330599 T1 AT E330599T1 AT 00902628 T AT00902628 T AT 00902628T AT 00902628 T AT00902628 T AT 00902628T AT E330599 T1 ATE330599 T1 AT E330599T1
Authority
AT
Austria
Prior art keywords
acute
angiotensin
treatment
myocardic
infarct
Prior art date
Application number
AT00902628T
Other languages
German (de)
English (en)
Inventor
Jessica M Mann
Pascale Oddou
Eric Michel Neuhart
Original Assignee
Novartis Pharma Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26153740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE330599(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh
Application granted granted Critical
Publication of ATE330599T1 publication Critical patent/ATE330599T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT00902628T 1999-01-26 2000-01-24 Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt ATE330599T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21

Publications (1)

Publication Number Publication Date
ATE330599T1 true ATE330599T1 (de) 2006-07-15

Family

ID=26153740

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00902628T ATE330599T1 (de) 1999-01-26 2000-01-24 Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt

Country Status (25)

Country Link
EP (2) EP1146872B1 (enExample)
JP (1) JP2002535367A (enExample)
KR (1) KR100674053B1 (enExample)
CN (1) CN1337879A (enExample)
AT (1) ATE330599T1 (enExample)
AU (1) AU766453C (enExample)
BR (1) BR0007686A (enExample)
CA (1) CA2360691A1 (enExample)
CY (1) CY1105257T1 (enExample)
CZ (1) CZ20012682A3 (enExample)
DE (1) DE60028928T2 (enExample)
DK (1) DK1146872T3 (enExample)
ES (1) ES2265910T3 (enExample)
HK (1) HK1041808B (enExample)
HU (1) HUP0105199A3 (enExample)
ID (1) ID29818A (enExample)
IL (2) IL144216A0 (enExample)
NO (1) NO20013459L (enExample)
NZ (1) NZ513039A (enExample)
PL (1) PL197161B1 (enExample)
PT (1) PT1146872E (enExample)
RU (2) RU2298405C2 (enExample)
SI (1) SI1146872T1 (enExample)
SK (1) SK10522001A3 (enExample)
WO (1) WO2000044378A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ297795B6 (cs) 1998-12-23 2007-03-28 Novartis Ag Tablety obsahující valsartan
EP1314425A4 (en) * 2000-08-30 2004-06-02 Sankyo Co MEDICINAL COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF HEART FAILURE
US7076287B2 (en) * 2000-12-29 2006-07-11 Ge Medical Systems Information Technologies, Inc. System and method for detecting new left bundle branch block for accelerating treatment of acute myocardial infarction
AU2002363087A1 (en) * 2001-10-18 2003-05-06 Novartis Ag Salts formed of an at1-receptor antagonist and a cardiovascular agent
CA2486121A1 (en) * 2002-05-17 2003-11-27 Novartis Ag Combination of angiotensin ii receptor blocker and beta-blocker for secondary prevention of myocardial infarction
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
SE0302331D0 (sv) * 2003-08-29 2003-08-29 Astrazeneca Ab New use II
TW200523257A (en) * 2003-09-26 2005-07-16 Novartis Ag Use of organic compounds
WO2005053687A1 (en) * 2003-11-25 2005-06-16 Novartis Ag Combination of organic compounds
WO2009087116A1 (en) * 2008-01-11 2009-07-16 Novartis Ag Use of spp100 for the treatment of acute mi
CN104086623B (zh) * 2014-07-02 2017-05-24 牡丹江友搏药业有限责任公司 一种新的具有降压和细胞保护作用的化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9027208D0 (en) * 1990-12-14 1991-02-06 Smithkline Beecham Plc Medicaments
EP0577025A3 (de) * 1992-07-01 1998-02-04 Hoechst Aktiengesellschaft Angiotensin-II-Rezeptorantagonisten zur Behandlung und Prophylaxe von koronaren Herzerkrankungen
FR2716882B1 (fr) * 1994-03-04 1996-04-05 Roussel Uclaf Utilisation de dérivés de l'imidazole au traitement d'affections impliquant les récepteurs AT1 et AT2 de l'Angiotensine, certains de ces produits, leur préparation, compositions pharmaceutiques.
FR2716883B1 (fr) * 1994-03-04 1996-04-26 Roussel Uclaf Nouveaux dérivés tétrasubstitués de l'imidazole, leur préparation, nouveaux intermédiaires obtenus, leur application à titre de médicaments, compositions pharmaceutiques les renfermant.
DE4432860A1 (de) * 1994-09-15 1996-03-21 Merck Patent Gmbh Imidazopyridine
GB9613470D0 (en) * 1996-06-27 1996-08-28 Ciba Geigy Ag Small solid oral dosage form
US5795904A (en) * 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach

Also Published As

Publication number Publication date
NZ513039A (en) 2003-11-28
SK10522001A3 (sk) 2001-12-03
RU2006135205A (ru) 2008-04-10
CY1105257T1 (el) 2010-03-03
CZ20012682A3 (cs) 2001-10-17
ID29818A (id) 2001-10-11
WO2000044378A1 (en) 2000-08-03
PT1146872E (pt) 2006-10-31
DK1146872T3 (da) 2006-10-16
HK1041808A1 (en) 2002-07-26
DE60028928T2 (de) 2007-01-04
DE60028928D1 (de) 2006-08-03
JP2002535367A (ja) 2002-10-22
HK1041808B (en) 2007-01-19
ES2265910T3 (es) 2007-03-01
EP1146872A1 (en) 2001-10-24
HUP0105199A2 (hu) 2002-04-29
BR0007686A (pt) 2001-11-06
EP1146872B1 (en) 2006-06-21
HUP0105199A3 (en) 2004-11-29
KR20020002379A (ko) 2002-01-09
KR100674053B1 (ko) 2007-01-25
RU2298405C2 (ru) 2007-05-10
AU766453B2 (en) 2003-10-16
CA2360691A1 (en) 2000-08-03
RU2345790C2 (ru) 2009-02-10
CN1337879A (zh) 2002-02-27
PL197161B1 (pl) 2008-03-31
NO20013459L (no) 2001-09-05
IL144216A (en) 2007-07-04
EP1714651A1 (en) 2006-10-25
IL144216A0 (en) 2002-05-23
NO20013459D0 (no) 2001-07-12
SI1146872T1 (sl) 2006-12-31
AU766453C (en) 2004-11-25
AU2439700A (en) 2000-08-18

Similar Documents

Publication Publication Date Title
BR0110028A (pt) Uso de antagonistas-ngf para a prevenção ou tratamento de dor visceral crÈnica
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
DE60039783D1 (de) Lfa-1 antagonisten und tnf-alpha antagonisten zur
ATE376832T1 (de) Verzögert freisetzende formulierungen von oxymorphon
NZ506188A (en) A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
NO20034311D0 (no) CCR5-antagonister for behandling av AIDS
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
NO963064D0 (no) Behandling av normotensive glaukoma med angiotensin-II-antagonister
ATE330599T1 (de) Verwendung von angiotensin ii rezeptorantagonisten zur behandlung von akutem myokardischen infarkt
MY124786A (en) Bis-arylsulfones
DE69432595D1 (de) Antagonisten des angiotensin ii-rezeptors zur behandlung von chronischen entzündlichen erkrankungen
DE60132851D1 (de) Arzneimittel zur Vorbeugung, Erleichterung oder Behandlung von Hypertension
CY1106365T1 (el) Συνδυασμος ενος αναστολεα pde και ενος ανταγωνιστη υποδοχεων λευκοτριενιου
ATE295183T1 (de) Mittel zur linderung von juckreiz, enthaltend pgd2- antagonisten
EE200100520A (et) N-(2-fenüül-4-aminobutüül)-1-naftamiidid neurokiniin-1-retseptori antagonistidena
AP2002002501A0 (en) Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
EE200100553A (et) Saredutandi ja selle farmatseutiliselt vastuvõetavate soolade kasutamine meeleoluhäirete, kohanemishäirete või segatüüpi ärev-depressiivsete häirete raviks või vältimiseks kasulike ravimite valmistamiseks
EA200601592A1 (ru) Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
AP1534A (en) Vitronectin receptor antagonists.
BR0000486A (pt) Antagonistas do neuropeptìdeo y
NO20033634L (no) GLyT-1-inhibitorer
DE60025705D1 (de) Antikonvulsive derivate zur behandlung von essentiellem tremor
MY131858A (en) Active ingredient combination for the pharmacological therapy of nicotine dependence
DE69923982D1 (de) Verwendung einer zusammensetzung enthaltend eine assoziation eines angiotensin ii at1 rezeptor antagonists und indomethacin zur herstellung eines arzneimittels zur behandlung von kronischen glomerulonephriten
ATE293975T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von kognitiven störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1146872

Country of ref document: EP

RZN Patent revoked